Phase 1 Bladder Cancer Trial, Recruiting NCT06916494 Sponsor: First Affiliated Hospital of Chongqing Medical University Condition: Bladder Cancer
Back to Bladder Cancer

Phase 1 Bladder Cancer Trial, Recruiting

NCT06916494
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with muscle-invasive bladder cancer (a type of bladder cancer that has grown into the muscle wall) at a specific stage that has not spread to lymph nodes or other parts of the body
  • People whose cancer did not respond after 2 rounds of a standard chemotherapy combination (called GC chemotherapy) given before surgery
  • People who have not previously been treated with immunotherapy or targeted therapy drugs
  • People whose tumor can be measured using a standard medical imaging method (confirm with trial site)
  • People who are in good general physical condition, able to carry out normal daily activities with little or no limitation (confirm with trial site)

Who may not be able to join:

  • People under 18 years of age
  • People with serious heart, brain, liver, or kidney disease
  • People who are severely malnourished
  • People with a mental illness that affects their ability to understand their situation or communicate clearly
  • People who have been diagnosed with cancer in another organ in addition to bladder cancer
  • People with a serious infection affecting the whole body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Xin Gou, Professor, The First Affiliated Hospital of Chongqing Medica University

Phone: 0086+13650518875

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
First Affiliated Hospital of Chongqing Medical University
Registry
ClinicalTrials.gov
Start date
1 May 2025
Est. completion
20 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Tumor microenvironment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov